BlackRock
PNT

BlackRock’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

BlackRock’s Portfolio PNT Stock Details PNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-6,635,892
Closed -$44.3M – 5468
2023
Q3 		$44.3M Buy
6,635,892
+285,792
+5% +$2.38M ﹤0.01% 2462
2023
Q2 		$57.5M Buy
6,350,100
+866,833
+16% +$7.65M ﹤0.01% 2398
2023
Q1 		$39.9M Buy
5,483,267
+89,829
+2% +$666K ﹤0.01% 2605
2022
Q4 		$39.3M Sell
5,393,438
-759,159
-12% -$5.63M ﹤0.01% 2629
2022
Q3 		$47.6M Buy
6,152,597
+16,099
+0.3% +$137K ﹤0.01% 2479
2022
Q2 		$41.8M Buy
6,136,498
+3,495,532
+132% +$26.7M ﹤0.01% 2610
2022
Q1 		$21M Sell
2,640,966
-347
-0% -$2.2K ﹤0.01% 3141
2021
Q4 		$14.8M Buy
2,641,313
+910,207
+53% +$6.83M ﹤0.01% 3449
2021
Q3 		$13.3M Buy
1,731,106
+236,290
+16% +$2.16M ﹤0.01% 3540
2021
Q2 		$15.4M Sell
1,494,816
-5,184
-0.3% -$52.7K ﹤0.01% 3449
2021
Q1 		$15.8M Hold
1,500,000
– – ﹤0.01% 3310
2020
Q4 		$20.9M Hold
1,500,000
– – ﹤0.01% 2987
2020
Q3 		$21.6M Buy
+1,500,000
New +$20.5M ﹤0.01% 2818

Other funds holding PNT

BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

BlackRock's PNT Position: Q4 2023 in Review

BlackRock sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q4 2023, closing a stake of 6,635,892 shares — an estimated $44.3M sold.

BlackRock first reported a position in PNT in Q3 2020 and held it in 13 quarters. The position peaked at $57.5M in Q2 2023. 1 fund tracked by Wall St. Rank holds PNT as of Q4 2023.

  • BlackRock reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • BlackRock sold 6,635,892 POINT Biopharma Global Inc. Common Stock shares in Q4 2023, an estimated $44.3M.
  • BlackRock first reported a position in POINT Biopharma Global Inc. Common Stock in Q3 2020 and held it in 13 quarters.
  • BlackRock's POINT Biopharma Global Inc. Common Stock position peaked at $57.5M in Q2 2023.
  • 1 fund tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q4 2023.

Based on BlackRock's 13F filing for Q4 2023, filed 13 Feb 2024.